Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 1, 2008, Pages 165-171

  Silva, Karina Lani ^a,b   Vasconcellos, Deborah Vidal ^a,b   Castro, Eric Delfraro De Paula ^a   Vasconcelos, Flavia Da Cunha ^a   Bigni, Ricardo ^a   Maia, Raquel Ciuvalschi ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Apoptosis; CLL; MDR; Pamidronate; Zoledronic acid

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FAULDPAMI; FLUDARABINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PAMIDRONIC ACID; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; DIPHOSPHONATES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENES, MDR; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PHENOTYPE;

EID: 42149098660     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0710-1     Document Type: Article

References (36)

1. Abbott BL (2006) Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 11:21-30
2. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F (2006) How I treat refractory CLL. Blood 107:1276-1283
3. Chin-Yee I, Alshammari S, Anderson L, Kadri M, Keeney M (1996) Comparison of two methods to detect P-glycoprotein in patients with chronic lymphocytic leukaemia. Clin Lab Haematol 18:99-104
4. Webb M, Brun M, McNiven M, Le Couteur D, Craft P (1998) MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol 102:710-717
5. Svoboda-Beusan I, Kusec R, Bendelja K, Tudoric-Ghemo I, Jaksic B, Pejsa V, Rabatic S, Vitale B (2000) The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica 85:1261-1267
6. Juszczynski P, Niewiarowski W, Krykowski E, Robak T, Warzocha K (2002) Expression of the multidrug resistance-associated protein (mrp) gene in chronic lymphocytic leukemia. Leuk Lymphoma 43:153-158
7. Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45:872-877
8. Matthews C, Catherwood MA, Larkin AM, Clynes M, Morris TC, Alexander HD (2006) MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk Lymphoma 47:2308-2313
9. Hosking D (2006) Pharmacological therapy of Paget's and other metabolic bone diseases. Bone 38:3-7
10. Borges JL, Bilezikian JP (2006) Update on osteoporosis therapy. Arq Bras Endocrinol Metabol 50:755-763
11. Hejdova M, Palicka V, Kucera Z, Vlcek J (2005) Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study. Pharm World Sci 27:149-153
12. Dunstan CR, Felsenberg D, Seibel MJ (2007) Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 4:42-55
13. Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12(20 Suppl):6222-6230
14. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S, Tonini G (2003) The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14:1468-1476
15. Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9:3-13
16. Nishida S, Kikuichi S, Haga H, Yoshioka S, Tsubaki M, Fujii K, Irimajiri K (2003) Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Biol Pharm Bull 26:96-100
17. Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y, Ueda T, Enjo F, Tokuda H, Ottmann OG, Maekawa T (2003) The third-generation bisphosphonate zoledronic acid synergistically augments the anti-Ph + leukemia activity of imatinib mesylate. Blood 102:2229-2235
18. Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, Ottmann OG, Maekawa T (2004) Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 79:37-43
19. Silva KL, Vasconcellos DV, Castro ED, Coelho AM, Linden R, Maia RC (2006) Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 11:277-285
20. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12:220-229
21. Senaratne SG, Colston KW (2002) Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4:18-23
22. Ural AU, Yilmaz MI, Avcu F, Pekel A, Zerman M, Nevruz O, Sengul A, Yalcin A (2003) The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 78:443-449
23. Chuah C, Barnes DJ, Kwok M, Corbin A, Deininger MW, Druker BJ, Melo JV (2005) Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia 19:1896-1904
24. Silva KL, Vasconcelos FC, Marques-Santos LF, Kwee JK, Maia RC (2003) CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype. Leuk Res 27:243-251
25. Moulin M, Dumontet C, Arrigo AP (2007) Sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia. Cancer Lett 250:117-127
26. Vasconcelos FC, Cavalcanti Jr GB, Silva KL, de Meis E, Kwee JK, Rumjanek VM, Maia RC (2007) Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res 31:445-454
27. Hu XF, Slater A, Kantharidis P, Rischin D, Juneja S, Rossi R, Lee G, Parkin JD, Zalcberg JR (1999) Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 93:4086-4095
28. Twentyman PR, Rhodes T, Rayner S (1994) A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 30A:1360-1369
29. Berenson J, Ravera C, Ma P et al (2000) Population pharmacokinetics of zometa [abstract] Proc ASCO 209a
30. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88(6):2095-2105
31. Coxon JP, Oades GM, Kirby RS, Colston KW (2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94(1):164-170
32. Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E, Sala R, Cerretti R, Mandelli F (1999) Clinical characteristics and out come of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 94:448-454
33. Molica S (2001) Prognostic factors in chronic lymphocytic leukemia. In: Cheson BD (ed) Chronic lymphoid leukemias. Marcel Dekker, New York, pp 231-260
34. Wall DM, el-Osta S, Tzelepis D, Bertoncello I, Kantharidis P, Chou ST, Zalcberg JR, Parkin JD (1997) Expression of mdr1 and mrp in the normal B-cell homologue of B-cell chronic lymphocytic leukaemia. Br J Haematol 96:697-707
35. Consoli U, Santonocito A, Stagno F, Fiumara P, Privitera A, Parisi G, Giustolisi GM, Pavone B, Palumbo GA, Di Raimondo F, Milone G, Guglielmo P, Giustolisi R (2002) Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 116:774-780
36. Yildiz M, Celik-Ozenci C, Akan S, Akan I, Sati L, Demir R, Savas B, Ozben T, Samur M, Ozdogan M, Artac M, Bozcuk H (2006) Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study. Cell Biol Int 30:278-282